Renal Insufficiency, Chronic clinical trials

The registry lists 3,094 studies for Renal Insufficiency, Chronic across more than 10 countries. 701 are recruiting or about to start. 1,909 of them are mainly about Renal Insufficiency, Chronic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Kidney Failure, Chronic too: 4,876 studies, 918 open.

ClinicalTrials.gov finds 5,016 studies for Renal Insufficiency, Chronic. How that becomes 3,085 here

This page counts the studies the registry files under Renal Insufficiency, Chronic, and those it files under no condition that list Renal Insufficiency, Chronicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

5,016Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−1,696Filed under a narrower condition, counted on its own pageKidney Failure, Chronic 1,677
−235Match it another way6 name it in the title and 229 by a synonym or other text the search reads.
3,085The count on this page

Get an email when these change. Save the Renal Insufficiency, Chronic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,631
Recruiting: 434
Status unknown: 347
Not yet recruiting: 223
Terminated: 180
Active, not recruiting: 140

Phase

Phase 2: 364
Phase 3: 356
Phase 4: 313
Phase 1: 212
Early Phase 1: 22

Where

United States: 988
China: 245
France: 238
Germany: 232
United Kingdom: 229
Canada: 215

Who runs them

Amgen (54) · AstraZeneca (50) · Bayer (49) · Assiut University (35) · Novo Nordisk A/S (29) · VA Office of Research and Development (22) · University of Colorado, Denver (21) · Brigham and Women's Hospital (21)

What is being tested here

Drugs under test in Renal Insufficiency, Chronic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Dapagliflozin	15	11	40
Finerenone	14	6	25
Semaglutide	9	3	14
Empagliflozin	6	3	20
Sodium Bicarbonate	4	3	19
HRS-1780	4	1	4
Sodium zirconium cyclosilicate	3	5	8
Canagliflozin	3	1	5
Patiromer	2	5	13
Spironolactone	2	2	11

Drug classes tested here SGLT2 inhibitors 21 open · Mineralocorticoid receptor antagonists (MRAs) 17 open · GLP-1 receptor agonists 13 open · Diuretics 5 open · Angiotensin receptor blockers (ARBs) 2 open

Coming up

55phase 3 studies under way

247studies finish main data collection within a year13 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism · Phase 3 · Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dec 2026Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V · Phase 3 · University of Texas Southwestern Medical Center
Dec 2026A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients · Phase 3 · Fundación para la Investigación del Hospital Clínico de Valencia
Dec 2026EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) · Phase 3 · Boehringer Ingelheim
Feb 2027Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial · Phase 3 · Hamilton Health Sciences Corporation
Apr 2027A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria · Phase 3 · Bayer
Apr 2027A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) · Phase 3 · Boehringer Ingelheim
Jun 2027A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis · Phase 3 · Amgen
Jul 2027The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD · Phase 3 · University Medical Center Groningen
Jul 2027Keeping RAASi Treatment With Optimal Potassium Control · Phase 3 · Fundación para la Investigación del Hospital Clínico de Valencia

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger. 45 (10%) take children under 18. 5 (1%) are for women only and 2 (<1%) for men only; 80 (18%) take healthy volunteers.

Recruiting studies that take each age, of 434
Age	Women	Men
10	32 (7%)	33 (8%)
18	349 (80%)	348 (80%)
30	362 (83%)	361 (83%)
40	372 (86%)	371 (85%)
50	386 (89%)	382 (88%)
65	391 (90%)	387 (89%)
75	355 (82%)	352 (81%)
85	293 (68%)	291 (67%)

Across all 3,094 studies, recruiting or not: 24% stop at 75 or younger and 12% at 65; 10% take children; 1% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Renal Insufficiency, Chronic studies take

Of 145 phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	12 mo5–27 · 109 studies	7 mo5–16 · 77 studies	—
Phase 1/2	25 mo12–55 · 22 studies	—	—
Phase 2	25 mo15–43 · 139 studies	19 mo12–31 · 80 studies	41 mo23–62 · 59 studies
Phase 2/3	21 mo9–56 · 11 studies	—	—
Phase 3	33 mo19–54 · 145 studies	29 mo18–49 · 104 studies	50 mo28–69 · 41 studies
Phase 4	43 mo22–67 · 116 studies	—	46 mo24–67 · 100 studies
Interventional, no phase	23 mo10–45 · 616 studies	23 mo10–43 · 40 studies	23 mo10–45 · 576 studies
Observational	45 mo22–191 · 325 studies	29 mo17–51 · 51 studies	59 mo24–192 · 274 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out